Lysine therapy of type 2 diabetic patients
Early Phase 1
- Conditions
- Type 2 diabetes.Non-insulin-dependent diabetes mellitus
- Registration Number
- IRCT2014120220184N1
- Lead Sponsor
- Iran National Science Foundation (INSF)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Inclusion Criteria: Glycated hemoglobin (HbA1c) = 7%; normal serum insulin level; no history of ketoacidosis, cancer, hyper- or hypothyroidism, diabetic ulcer, chronic renal failure, liver cirrhosis, feverish diseases and consumption of corticosteroids; with serum creatinine = 2 mg/dl; no symptom of hypoinsulinemia such as ketonuria, weight loss; serum glucose level more than 400 mg/dl.
Exclusion Criteria
no response to oral agents; need for insulin therapy; appearance of diabetic ulcer or feverish diseases during treatment.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting Blood Sugar. Timepoint: 3 Months. Method of measurement: Enzymatic Colorimetric.;Hemoglobin A1c. Timepoint: 3 Months. Method of measurement: HPLC.
- Secondary Outcome Measures
Name Time Method Insulin Resistance. Timepoint: 3 months. Method of measurement: ELISA.